BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morand EF, Furie RA, Bruce IN, Vital EM, Dall'era M, Maho E, Pineda L, Tummala R. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. The Lancet Rheumatology 2022;4:e282-92. [DOI: 10.1016/s2665-9913(21)00317-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Lorenzo-Vizcaya A, Isenberg DA. Clinical trials in systemic lupus erythematosus: the dilemma-Why have phase III trials failed to confirm the promising results of phase II trials? Ann Rheum Dis 2023;82:169-74. [PMID: 36202589 DOI: 10.1136/ard-2022-222839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 2023;75:242-52. [PMID: 36369798 DOI: 10.1002/art.42391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis Rheumatol 2023;75:253-65. [PMID: 36369793 DOI: 10.1002/art.42392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Banjari M, Touma Z, Gladman DD. Improving measures of disease activity in systemic lupus erythematosus. Expert Rev Clin Immunol 2023;19:193-202. [PMID: 36503376 DOI: 10.1080/1744666X.2023.2156339] [Reference Citation Analysis]
5 Bruce IN, van Vollenhoven RF, Psachoulia K, Lindholm C, Maho E, Tummala R. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials. Lupus Sci Med 2023;10:e000761. [PMID: 36639192 DOI: 10.1136/lupus-2022-000761] [Reference Citation Analysis]
6 Felten R, Scherlinger M, Mertz P, Chasset F, Arnaud L. New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. Joint Bone Spine 2023;90:105523. [PMID: 36623799 DOI: 10.1016/j.jbspin.2023.105523] [Reference Citation Analysis]
7 Aringer M, Nitschmann S. Anifrolumab für die Therapie des systemischen Lupus erythematodes. Innere Medizin 2022;63:1009-1012. [DOI: 10.1007/s00108-022-01389-7] [Reference Citation Analysis]
8 Lamb YN. Anifrolumab in systemic lupus erythematosus: a profile of its use. Drugs Ther Perspect 2022;38:293-300. [DOI: 10.1007/s40267-022-00925-7] [Reference Citation Analysis]
9 Aringer M, Costenbader K, Dörner T, Johnson SR. Advances in SLE classification criteria. J Autoimmun 2022;:102845. [PMID: 35725680 DOI: 10.1016/j.jaut.2022.102845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Plüß M, Piantoni S, Wincup C, Korsten P. Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach. J Clin Med 2022;11:3449. [PMID: 35743519 DOI: 10.3390/jcm11123449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis. Hum Vaccin Immunother 2022;:2072143. [PMID: 35588699 DOI: 10.1080/21645515.2022.2072143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Aringer M. Who will respond to type I interferon receptor blockade in SLE? The Lancet Rheumatology 2022;4:e234-e236. [DOI: 10.1016/s2665-9913(21)00370-2] [Reference Citation Analysis]